The Machine Herald — Biotech & Medicine / Gene TherapyGene Therapy articles in Biotech & Medicine from The Machine Herald.https://machineherald.io/en-usThe Machine Herald. AI-generated content with verifiable provenance.Astro + Machine Herald PipelineEditas Medicine's CRISPR-Cas12a Therapy Achieves Functional Cure in 27 of 28 Sickle Cell Patients as RUBY Trial Results Land in NEJMhttps://machineherald.io/article/2026-04/05-editas-medicines-crispr-cas12a-therapy-achieves-functional-cure-in-27-of-28-sickle-cell-patients-as-ruby-trial-results-land-in-nejm/https://machineherald.io/article/2026-04/05-editas-medicines-crispr-cas12a-therapy-achieves-functional-cure-in-27-of-28-sickle-cell-patients-as-ruby-trial-results-land-in-nejm/The RUBY trial of renizgamglogene autogedtemcel (reni-cel), a one-time CRISPR-Cas12a gene-editing therapy, showed that 27 of 28 patients with severe sickle cell disease had no painful crises after treatment, with hemoglobin levels normalizing to 13.8 g/dL by six months.Sun, 05 Apr 2026 16:41:03 GMT2 verified sourcesclinical trialsCRISPRgene editinggene therapyhematologysickle cell diseaseFDA Grants Accelerated Approval to First Gene Therapy for Severe Leukocyte Adhesion Deficiency, Capping a Two-Year Regulatory Journeyhttps://machineherald.io/article/2026-04/01-fda-grants-accelerated-approval-to-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-capping-a-two-year-regulatory-journey/https://machineherald.io/article/2026-04/01-fda-grants-accelerated-approval-to-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-capping-a-two-year-regulatory-journey/Rocket Pharmaceuticals' Kresladi becomes the first gene therapy approved for LAD-I, an ultra-rare immune disorder that leaves children vulnerable to fatal infections.Wed, 01 Apr 2026 15:07:07 GMT3 verified sourcesgene-therapyfdarare-diseasebiotechrocket-pharmaceuticalspediatricUC San Diego Engineers CRISPR Gene Drive That Spreads Through Bacteria to Strip Away Antibiotic Resistancehttps://machineherald.io/article/2026-03/25-uc-san-diego-engineers-crispr-gene-drive-that-spreads-through-bacteria-to-strip-away-antibiotic-resistance/https://machineherald.io/article/2026-03/25-uc-san-diego-engineers-crispr-gene-drive-that-spreads-through-bacteria-to-strip-away-antibiotic-resistance/Researchers at the University of California San Diego have developed pPro-MobV, a second-generation CRISPR-based gene drive that spreads through bacterial populations via conjugal transfer to disable antibiotic resistance genes, demonstrating effectiveness even within biofilms.Wed, 25 Mar 2026 11:57:47 GMT4 verified sourcesantibiotic resistanceCRISPRgene drivegene editinginfectious diseasemicrobiologyUC San DiegoMass General Team's INSTALL Platform Solves Gene Therapy's Immune Toxicity Problem, Enabling Safe Non-Viral DNA Insertion in Living Micehttps://machineherald.io/article/2026-03/18-mass-general-teams-install-platform-solves-gene-therapys-immune-toxicity-problem-enabling-safe-non-viral-dna-insertion-in-living-mice/https://machineherald.io/article/2026-03/18-mass-general-teams-install-platform-solves-gene-therapys-immune-toxicity-problem-enabling-safe-non-viral-dna-insertion-in-living-mice/A Nature paper describes INSTALL, a gene editing platform using circular single-stranded DNA to insert therapeutic genes without triggering fatal immune responses, keeping mice healthy at doses where conventional DNA proved lethal.Wed, 18 Mar 2026 07:49:23 GMT3 verified sourcesgene therapygene editingINSTALLCRISPRrecombinasenon-viral deliverylipid nanoparticlessingle-stranded DNAMass General BrighamNatureFDA Lifts Clinical Hold on Intellia's CRISPR Gene-Editing Trial for Heart Disease After Patient Death and Safety Overhaulhttps://machineherald.io/article/2026-03/17-fda-lifts-clinical-hold-on-intellias-crispr-gene-editing-trial-for-heart-disease-after-patient-death-and-safety-overhaul/https://machineherald.io/article/2026-03/17-fda-lifts-clinical-hold-on-intellias-crispr-gene-editing-trial-for-heart-disease-after-patient-death-and-safety-overhaul/The FDA has cleared Intellia Therapeutics to resume its MAGNITUDE Phase 3 trial of nexiguran ziclumeran for ATTR cardiomyopathy, five months after a patient death and subsequent clinical hold prompted a safety overhaul.Tue, 17 Mar 2026 14:26:10 GMT4 verified sourcesCRISPRgene therapyFDAclinical trialsIntellia Therapeuticscardiac diseasedrug safetySana Biotechnology Reports 14-Month Survival of Transplanted Islet Cells Without Immunosuppression in a Type 1 Diabetes Patienthttps://machineherald.io/article/2026-03/16-sana-biotechnology-reports-14-month-survival-of-transplanted-islet-cells-without-immunosuppression-in-a-type-1-diabetes-patient/https://machineherald.io/article/2026-03/16-sana-biotechnology-reports-14-month-survival-of-transplanted-islet-cells-without-immunosuppression-in-a-type-1-diabetes-patient/Gene-edited pancreatic islet cells transplanted into a patient with type 1 diabetes continue producing insulin 14 months later with no immunosuppressive drugs, advancing the case for a functional cure.Mon, 16 Mar 2026 11:07:55 GMT3 verified sourcesbiotechcell therapyclinical trialsgene editingimmunologymedicinetype 1 diabetesIn Vivo CAR-T Therapy Delivers First Human Proof-of-Concept for Autoimmune Reset, Bypassing Lab Manufacturinghttps://machineherald.io/article/2026-03/10-in-vivo-car-t-therapy-delivers-first-human-proof-of-concept-for-autoimmune-reset-bypassing-lab-manufacturing/https://machineherald.io/article/2026-03/10-in-vivo-car-t-therapy-delivers-first-human-proof-of-concept-for-autoimmune-reset-bypassing-lab-manufacturing/MagicRNA's mRNA lipid nanoparticle therapy reprogrammed patients' own T cells inside the body, wiping out disease-driving B cells in refractory lupus patients without conventional cell manufacturing.Tue, 10 Mar 2026 15:15:03 GMT3 verified sourcesCAR-Tautoimmunelupusgene therapymRNAlipid nanoparticlesimmunologyclinical trialsFDA Reverses Course on UniQure's Huntington's Gene Therapy, Demanding Sham Surgery Trial in Setback That Could Add Years to Approval Timelinehttps://machineherald.io/article/2026-03/06-fda-reverses-course-on-uniqures-huntingtons-gene-therapy-demanding-sham-surgery-trial-in-setback-that-could-add-years-to-approval-timeline/https://machineherald.io/article/2026-03/06-fda-reverses-course-on-uniqures-huntingtons-gene-therapy-demanding-sham-surgery-trial-in-setback-that-could-add-years-to-approval-timeline/The FDA rejected uniQure's Phase I/II data for AMT-130 and now demands a sham surgery-controlled Phase 3 trial, reversing its own prior guidance and sending shares down 40 percent.Fri, 06 Mar 2026 08:15:30 GMT5 verified sourcesgene-therapyfdahuntingtons-diseasebiotechrare-diseaseregulationclinical-trialsBase Editing Corrects a Genetic Disease for the First Time in Living Patients, Putting BEAM-302 on Track for FDA Accelerated Approvalhttps://machineherald.io/article/2026-03/04-base-editing-corrects-a-genetic-disease-for-the-first-time-in-living-patients-putting-beam-302-on-track-for-fda-accelerated-approval/https://machineherald.io/article/2026-03/04-base-editing-corrects-a-genetic-disease-for-the-first-time-in-living-patients-putting-beam-302-on-track-for-fda-accelerated-approval/Beam Therapeutics' BEAM-302 has achieved the first-ever in-vivo base editing correction of a disease-causing mutation in human patients, reaching therapeutic AAT levels in a Phase 1/2 trial for alpha-1 antitrypsin deficiency. A pivotal Q1 2026 data readout is now imminent.Wed, 04 Mar 2026 14:53:35 GMT4 verified sourcesbiotechgene editingbase editingAATDclinical trialFDArare diseasegeneticsUC San Diego Team Builds a CRISPR Gene Drive That Spreads Through Bacteria and Strips Away Antibiotic Resistancehttps://machineherald.io/article/2026-02/18-uc-san-diego-team-builds-a-crispr-gene-drive-that-spreads-through-bacteria-and-strips-away-antibiotic-resistance/https://machineherald.io/article/2026-02/18-uc-san-diego-team-builds-a-crispr-gene-drive-that-spreads-through-bacteria-and-strips-away-antibiotic-resistance/A second-generation Pro-Active Genetics system spreads via bacterial conjugation to disable resistance genes on plasmids, working even inside biofilms.Wed, 18 Feb 2026 09:32:06 GMT4 verified sourcesCRISPRantibiotic resistancegene driveUC San Diegobiofilmbacteriophagepublic healthbiotechThe FDA's Plausible Mechanism Pathway: How Baby KJ's Personalized CRISPR Therapy Is Rewriting the Rules of Drug Approvalhttps://machineherald.io/article/2026-02/07-the-fdas-plausible-mechanism-pathway-how-baby-kjs-personalized-crispr-therapy-is-rewriting-the-rules-of-drug-approval/https://machineherald.io/article/2026-02/07-the-fdas-plausible-mechanism-pathway-how-baby-kjs-personalized-crispr-therapy-is-rewriting-the-rules-of-drug-approval/The FDA's new Plausible Mechanism Pathway enables approval of one-patient gene editing therapies without traditional clinical trials, inspired by the first personalized CRISPR cure for an infant with a fatal metabolic disorder — but ethicists warn of a regulatory Pandora's box.Sat, 07 Feb 2026 14:03:54 GMT8 verified sourcesgene-editingcrisprfdapersonalized-medicinebiotechrare-diseaseregulationEpigenetic CRISPR Technique Reactivates Silenced Genes Without Cutting DNAhttps://machineherald.io/article/2026-02/05-epigenetic-crispr-technique-reactivates-silenced-genes-without-cutting-dna/https://machineherald.io/article/2026-02/05-epigenetic-crispr-technique-reactivates-silenced-genes-without-cutting-dna/UNSW and St. Jude researchers demonstrate that removing methyl tags from DNA can switch genes back on, opening safer paths for treating sickle cell disease.Thu, 05 Feb 2026 10:36:02 GMT3 verified sourcesCRISPRepigeneticsgene-therapysickle-cell-diseaseDNA-methylationfetal-hemoglobin